EMBR-21. CLINICALLY TRACTABLE OUTCOME PREDICTION OF GROUP 3/4 MEDULLOBLASTOMA BASED ON TPD52 IMMUNOHISTOCHEMISTRY: A MULTICOHORT STUDY

Alberto Delaidelli; Christopher Dunham; Mariarita Santi; Gian Luca Negri; Joanna Triscott; Olga Zheludkova; Andrey Golanov; Marina Ryzhova; Konstantin Okonechnikov; Daniel Schrimpf; Michael D. Taylor; Poul H. Sorensen

doi:https://doi.org/10.1093/neuonc/noab090.039

doi.org/10.1093/neuonc/noab090.039

EMBR-21. CLINICALLY TRACTABLE OUTCOME PREDICTION OF GROUP 3/4 MEDULLOBLASTOMA BASED ON TPD52 IMMUNOHISTOCHEMISTRY: A MULTICOHORT STUDY

,

,

..., Poul H. Sorensen

36

Neuro-Oncology15.90

Volume: 23, Issue: Supplement_1, Pages: i10 - i10

Published: Jun 1, 2021

Abstract

Background International consensus and the 2021 WHO classification recognize eight molecular subtypes among Group 3/4 medulloblastoma (representing ~60% of tumors). However, very few clinical centers worldwide possess the technical capabilities to determine DNA-methylation patterns or other molecular parameters of high-risk for Group 3/4 tumors. As a result, biomarker-driven risk stratification and therapy assignment constitutes a major...

Paper Fields

Paper Details

Title

EMBR-21. CLINICALLY TRACTABLE OUTCOME PREDICTION OF GROUP 3/4 MEDULLOBLASTOMA BASED ON TPD52 IMMUNOHISTOCHEMISTRY: A MULTICOHORT STUDY

DOI

doi.org/10.1093/neuonc/noab090.039

Published Date

Jun 1, 2021

Journal

Neuro-Oncology

Volume

23

Issue

Supplement_1

Pages

i10 - i10

Citation AnalysisPro

You’ll need to upgrade your plan to Pro

Looking to understand the true influence of a researcher’s work across journals & affiliations?

Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.

Learn more

Notes

History